We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

33 hedge funds and large institutions have $1.23M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

18% more funds holding

Funds holding: 28 → 33 (+5)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

42% less capital invested

Capital invested by funds: $2.13M → $1.23M (-$900K)

Holders
33
Holders Change
+5
Holders Change %
+17.86%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$36.1K
2
Millennium Management
Millennium Management
New York
+$21.4K
3
E
Ergoteles
New York
+$17.9K
4
Jane Street
Jane Street
New York
+$16.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$12.5K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$181K
2
BlackRock
BlackRock
New York
-$183
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$153
4
Osaic Holdings
Osaic Holdings
Arizona
-$99
5
TC
Truvestments Capital
Florida
-$17
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$323K – – –
LFCM
2
Long Focus Capital Management
Puerto Rico
$236K – – –
BBA
3
Baker Bros. Advisors
New York
$179K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$131K -$181K -182,877 -50%
BlackRock
5
BlackRock
New York
$54.6K -$183 -185 -0.2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$52K -$153 -155 -0.2%
BC
7
Boxer Capital
California
$41K – – –
BFM
8
Boothbay Fund Management
New York
$32.4K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$30.5K +$12.5K +12,616 +42%
HF
10
HRT Financial
New York
$26K +$36.1K +36,470 New
State Street
11
State Street
Massachusetts
$19.6K – – –
Millennium Management
12
Millennium Management
New York
$16K +$21.4K +21,595 New
E
13
Ergoteles
New York
$13K +$17.9K +18,105 New
Jane Street
14
Jane Street
New York
$11.8K +$16.2K +16,322 New
Renaissance Technologies
15
Renaissance Technologies
New York
$10K – – –
Morgan Stanley
16
Morgan Stanley
New York
$9.85K +$4.96K +5,013 +58%
SRC
17
Shufro Rose & Co
New York
$9.32K – – –
TRCT
18
Tower Research Capital (TRC)
New York
$8K +$1.79K +1,813 +19%
Northern Trust
19
Northern Trust
Illinois
$7.91K – – –
LPL Financial
20
LPL Financial
California
$7.58K – – –
TCM
21
Tekla Capital Management
Massachusetts
$4.32K – – –
UBS Group
22
UBS Group
Switzerland
$2.53K +$3.48K +3,510 New
Osaic Holdings
23
Osaic Holdings
Arizona
$1.01K -$99 -100 -3%
Group One Trading
24
Group One Trading
Illinois
$768 – – –
Wells Fargo
25
Wells Fargo
California
$562 +$2 +2 +0.3%
1
2

BLCM Hedge Fund Activity: Q4 2022 in Review

33 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2022, worth a combined $1.23M — down 42% from $2.13M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLCM positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $36.1K. The largest seller was Vanguard Group, cutting an estimated $181K.

  • 33 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2022, up from 28 in Q3 2022.
  • Funds reported $1.23M of Bellicum Pharmaceuticals, Inc. stock for Q4 2022, down 42% quarter-over-quarter.
  • 7 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2022 and 1 closed out, a net change of +6 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2022 was HRT Financial, an estimated $36.1K added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2022 was Vanguard Group, an estimated $181K sold.

Based on aggregated 13F filings for Q4 2022.